Thanks to Carpediem for this old AMLN post that I feel is on point today.
<<Bydureon will ultimately be approved, but AMLN may no longer be an independent company by the time of approval. Any buyout before approval will deprive long term AMLN investors of a return commensurate with the risk they have undertaken. This, and other recent examples, of bureaucratic intransigence must cause investors to re-evaluate the wisdom of investing in biotech.>>
Well...Provenge was fianlly approved. But the fight to discredit it continues.
Will some big pharma now purchase it for pennies on the dollar compared to what the true value should have been...?
Is the message finally getting out that investing in small biotechs may never pay off because the game is rigged in favor of the big players...?
What happens in the future if some new biotech startup with lots of potential tries to do an initial public offering and no little guys like us, Saul included, show up to buy..?
Would the last innovative little biotech to leave the USA please turn out the lights...?